The Membrane Proteinase 3 Expression on Neutrophils Was Downregulated After Treatment With Infliximab in Patients With Rheumatoid Arthritis

• Published in: Clinical and applied thrombosis/hemostasis 2008-04, Vol.14 (2), p.186-192
• Main Authors: Matsumoto, Takeshi, Kaneko, Toshihiro, Seto, Masashi, Wada, Hideo, Kobayashi, Toshihiko, Nakatani, Kaname, Tonomura, Harue, Tono, Yasutaka, Ohyabu, Mariko, Nobori, Tsutomu, Shiku, Hiroshi, Sudo, Akihiro, Uchida, Atsumasa, Stearns Kurosawa, Deborah J., Kurosawa, Shinichiro
• Format: Article
• Language: English
• Subjects: Adult; Antibodies, Monoclonal - therapeutic use; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - enzymology; Cell Membrane - enzymology; Down-Regulation; Female; Humans; Immunotherapy; Infliximab; Male; Monoclonal antibodies; Myeloblastin - analysis; Myeloblastin - antagonists & inhibitors; Neutrophils; Neutrophils - enzymology; Protease Inhibitors - pharmacology; Rheumatoid arthritis; Tumor Necrosis Factor-alpha - antagonists & inhibitors
• ISSN: 1076-0296; 1938-2723
• DOI: 10.1177/1076029607303961

Proteinase 3 (PR3) expression on neutrophils was examined in rheumatoid arthritis (RA) patients before and after antitumor necrosis factor (TNF)-α therapy. Membrane PR3 expression from patients with either an infection or RA significantly increased. Membrane PR3 expression on neutrophils from RA patients treated with infliximab (anti-TNF-α antibody) therapy was less than in those without such treatment in a resting state, but the expression later increased after stimulation in vitro. Membrane PR3 expression increased because of the stimulation of TNFα, whereas it was significantly suppressed by plasma or α1-proteinase inhibitor. The condition of patients with RA improved after treatment with infliximab. Membrane PR3 expression on neutrophils in RA patients was downregulated by infliximab. As a result, PR3 might play an important role in the neutrophil-mediated inflammatory reaction in patients with either RA or an infection.